About Mesosil
Mesosil is a company based in Toronto (Canada) founded in 2016. Mesosil has raised $1.6 million across 2 funding rounds from investors including GreenSky Ventures and UTEST. Mesosil offers products and services including Mesosil™ 500. Mesosil operates in a competitive market with competitors including AFYREN, Spore Biotechnologies, Celsis, Biopsin and Source Molecular, among others.
- Headquarter Toronto, Canada
- SectorsHealthcare
- Website mesosil.com
- Social LinkedIn
- Total Equity Funding$1.6 M (USD)
in 2 rounds
- Latest Funding Round$1.6 M (USD), Seed
Jun 14, 2024
- InvestorsGreenSky Ventures
& 1 more
Products & Services of Mesosil
Mesosil offers a comprehensive portfolio of products and services, including Mesosil™ 500.
Enables sustained release of agents to prevent infections in medical applications.
Funding Insights of Mesosil
Mesosil has successfully raised a total of $1.6M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.6 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.6M
- Total Rounds 2
- Last Round Seed — $1.6M
- Investors Count 2
All 2 funding rounds of Mesosil with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Mesosil
Mesosil has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include GreenSky Ventures and UTEST.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage Canadian B2B startups are funded by GreenSky Ventures. | 2015 | greensky.vc | Toronto, Canada | |
Early-stage technology incubator is operated by University of Toronto. | – | utest.to | Toronto, Canada |
Investor details for Mesosil
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Mesosil
3 dated milestones of Mesosil across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Mesosil is founded.
- Funding First funding round.
- Funding Latest funding round, Seed, of $1.6M.
Competitors of Mesosil
Mesosil operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AFYREN, Spore Biotechnologies, Celsis, Biopsin and Source Molecular, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| afyren.com | 2012 | Paris, France | $25.6M | – | Analytical services are provided for microbiology, chemistry, and bioprocesses sectors. | |
| spore.bio | 2022 | Paris, France | $31.6M | – | Microbial detection technology is developed for life science industries. | |
| celsis.com | 1994 | Chicago, United States | $36.8M | – | Rapid microbial screening systems are manufactured for quality control testing. | |
| biopsin.com | 2018 | Singapore | $175,000 | – | Real-time microbial detection system is developed for product testing. | |
| sourcemolecular.com | 2002 | Miami, United States | $1.6M | – | Technology for microbial source tracking is provided by Source Molecular. | |
| tepnelpharmaservices.com | 2013 | Wythenshawe, United Kingdom | – | 33 | Provider of analytical and quality testing services for drug development and diagnostics | |
| ncimb.com | 1982 | Scotland | $2.3M | – | Biorepository, microbial collections, and microbiology services are provided globally. | |
| microbium.si | 2015 | Ljubljana, Slovenia | – | – | Microorganism detection and elimination services are provided for industrial products. | |
| sterile.com | 1981 | Philadelphia, United States | – | 197 | Microbiological testing and sterile cleanroom products are provided. |
Detailed competitors of Mesosil
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mesosil
Complete news archive for Mesosil
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Similar companies to Mesosil
10 companies that operate in the same segment as Mesosil (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Frequently Asked Questions about Mesosil
Mesosil was founded in 2016.
Mesosil is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Mesosil is a funded company, having raised a total of $1.6M across 2 funding rounds to date.
Mesosil was founded in 2016 in Toronto, Canada, within the biotechnology sector. Antimicrobial materials are developed by the company to address infections at the medical device-tissue interface. These materials function as local antibacterial fillers based on self-assembled structures. Operations focus on applications such as dental restoratives and implant surfaces, supporting medical device enhancements in a regulated industry.
Mesosil's top competitors include AFYREN, Spore Biotechnologies and NCIMB.
Mesosil offers Mesosil™ 500.
Mesosil has 2 investors. Key investors include GreenSky Ventures, and UTEST.